Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JORGE TOMAS CASO

Allopathic & Osteopathic Physicians Family Medicine

NPI
1457308157
CMS profile
201338
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$11.57

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $11.57 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $11.57 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JORGE TOMAS CASO

NPI 1457308157 · CMS profile ID 201338

Allopathic & Osteopathic Physicians / Family Medicine

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JORGE TOMAS CASO, NPI 1457308157, CMS profile ID 201338. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JORGE TOMAS CASO, NPI 1457308157, CMS profile ID 201338. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JORGE TOMAS CASO, NPI 1457308157, CMS profile ID 201338, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1457308157?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $11.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $11.5709/24/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 738478165 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2020 $11.57 1
PY2022 $1,200.00 1
PY2023 $4,459.41 20
PY2024 $1,274.65 11
PY2025 $35.85 1

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2020, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2020 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $5,513,175.40 309
PY2024 Recipient $2,105.91 13
PY2024 Principal investigator $5,484,672.89 220
PY2023 Recipient $1,815.05 10
PY2023 Principal investigator $6,619,562.71 1,445
PY2022 Principal investigator $4,761,350.73 1,335
PY2021 Principal investigator $244,385.00 24
PY2019 Principal investigator $19,780.00 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

233 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ModernaTX, Inc. $75.13 12/30/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131029
Principal investigator 1 ModernaTX, Inc. $500.00 12/30/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131049
Principal investigator 1 SANOFI PASTEUR INC. $16,000.00 12/27/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128699302
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 12/27/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128699304
Principal investigator 1 SANOFI PASTEUR INC. $3,000.00 12/27/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128699306
Principal investigator 1 SANOFI PASTEUR INC. $6,000.00 12/27/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128699308
Principal investigator 1 SANOFI PASTEUR INC. $50.00 12/27/2024 Non-covered Recipient Entity
Suncoast Research Associates, Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128702148
Principal investigator 1 SANOFI PASTEUR INC. $660.00 12/27/2024 Non-covered Recipient Entity
Suncoast Research Associates, Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128702150
Principal investigator 1 ModernaTX, Inc. $249.45 12/26/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131027
Principal investigator 1 ModernaTX, Inc. $1,500.00 12/24/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131047
Principal investigator 1 ModernaTX, Inc. $76,763.34 12/23/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147131033
Principal investigator 1 ModernaTX, Inc. $19,675.34 12/23/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131037
Principal investigator 1 ModernaTX, Inc. $412,081.03 12/19/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147131031
Principal investigator 1 ModernaTX, Inc. $138,381.16 12/19/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131035
Principal investigator 1 ModernaTX, Inc. $25,781.08 12/19/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147131053
Principal investigator 1 Bavarian Nordic A/S $200.00 12/18/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 1119663254
Principal investigator 1 Janssen Research & Development, LLC $1,452.00 12/16/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956993
Principal investigator 1 Bavarian Nordic A/S $3,933.27 12/13/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 1119663246
Principal investigator 1 Janssen Research & Development, LLC $620.00 12/11/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078957133
Principal investigator 1 ModernaTX, Inc. $68.30 12/11/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147131025
Principal investigator 1 ModernaTX, Inc. $335.18 12/06/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147130823
Principal investigator 1 ModernaTX, Inc. $236.25 12/06/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147130825
Principal investigator 1 ModernaTX, Inc. $32,504.59 12/06/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147130827
Principal investigator 1 SANOFI PASTEUR INC. $1,031.70 12/02/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128699258
Principal investigator 1 ModernaTX, Inc. $671,690.40 11/27/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147131001
Principal investigator 1 Novavax Inc $2,323.68 11/27/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123376815
Principal investigator 1 SANOFI PASTEUR INC. $33,189.89 11/22/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699262
Principal investigator 1 ModernaTX, Inc. $1,289.21 11/21/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147131005
Principal investigator 1 ModernaTX, Inc. $7,724.12 11/21/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147131011
Principal investigator 1 Novavax Inc $120.00 11/21/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375661
Principal investigator 1 Novavax Inc $225.00 11/21/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375663
Principal investigator 1 Bavarian Nordic A/S $28,007.50 11/20/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 1119663244
Principal investigator 1 Janssen Research & Development, LLC $978.00 11/20/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078957017
Principal investigator 1 ModernaTX, Inc. $23,193.30 11/20/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130821
Principal investigator 1 Novavax Inc $10,950.00 11/14/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123377905
Principal investigator 1 ModernaTX, Inc. $75.13 11/12/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147130995
Principal investigator 1 ModernaTX, Inc. $12,000.00 11/08/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147130997
Principal investigator 1 Novavax Inc $1,300.00 11/07/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375141
Principal investigator 1 Janssen Research & Development, LLC $3,372.00 11/06/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078957471
Principal investigator 1 ModernaTX, Inc. $1,200.00 11/06/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147131009
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $19,999.31 11/01/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1095480844
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $22,490.30 11/01/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
A Phase 2, Randomized, Double-blind, Active-controlled, Dose-ranging, Parallel-design Study of the Efficacy and Safety of Oral VX-993 in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1095481478
Principal investigator 1 ModernaTX, Inc. $204.00 10/31/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147130975
Principal investigator 1 ModernaTX, Inc. $102.45 10/29/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147130977
Principal investigator 1 Bavarian Nordic A/S $1,200.00 10/25/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 1119663252
Principal investigator 1 ModernaTX, Inc. $3,121.00 10/25/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147130789
Principal investigator 1 ModernaTX, Inc. $2,495.00 10/25/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147130791
Principal investigator 1 ModernaTX, Inc. $1,796.00 10/25/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147130793
Principal investigator 1 ModernaTX, Inc. $1,000.00 10/25/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147130795
Principal investigator 1 SANOFI PASTEUR INC. $8,931.24 10/25/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699264
Recipient SANOFI PASTEUR INC. $77.00 10/24/2024 Covered Recipient Physician Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1128698398
Recipient SANOFI PASTEUR INC. $81.00 10/24/2024 Covered Recipient Physician Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1128698400
Recipient SANOFI PASTEUR INC. $55.00 10/24/2024 Covered Recipient Physician Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1128698402
Recipient SANOFI PASTEUR INC. $55.00 10/24/2024 Covered Recipient Physician Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1128698404
Principal investigator 1 Bavarian Nordic A/S $1,180.70 10/23/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119663248
Principal investigator 1 Bavarian Nordic A/S $400.20 10/23/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119663250
Principal investigator 1 Bavarian Nordic A/S $43,064.04 10/23/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119663256
Principal investigator 1 Janssen Research & Development, LLC $634.00 10/23/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078957433
Recipient SANOFI PASTEUR INC. $75.00 10/23/2024 Covered Recipient Physician Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1128698388
Recipient SANOFI PASTEUR INC. $55.00 10/23/2024 Covered Recipient Physician Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1128698390
Recipient SANOFI PASTEUR INC. $85.00 10/23/2024 Covered Recipient Physician Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1128698392
Recipient SANOFI PASTEUR INC. $55.00 10/23/2024 Covered Recipient Physician Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1128698394
Recipient SANOFI PASTEUR INC. $203.00 10/23/2024 Covered Recipient Physician Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1128698396
Recipient SANOFI PASTEUR INC. $375.55 10/22/2024 Covered Recipient Physician Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1128698380
Recipient SANOFI PASTEUR INC. $677.82 10/22/2024 Covered Recipient Physician Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1128698382
Recipient SANOFI PASTEUR INC. $108.54 10/22/2024 Covered Recipient Physician Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1128698384
Recipient SANOFI PASTEUR INC. $203.00 10/22/2024 Covered Recipient Physician Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older No dispute reported 06/30/2026 1128698386
Principal investigator 1 ModernaTX, Inc. $25,359.53 10/16/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130813
Principal investigator 1 ModernaTX, Inc. $49.89 10/16/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147130973
Principal investigator 1 SANOFI PASTEUR INC. $28,772.10 10/11/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699260
Principal investigator 1 ModernaTX, Inc. $1,210.40 10/03/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147130981
Principal investigator 1 ModernaTX, Inc. $1,120.50 10/02/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147130785
Principal investigator 1 ModernaTX, Inc. $775.00 10/01/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147130787
Principal investigator 1 ModernaTX, Inc. $414.00 10/01/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130815
Principal investigator 1 Janssen Research & Development, LLC $845.00 09/25/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078957169
Principal investigator 1 ModernaTX, Inc. $45,818.19 09/25/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147130959
Principal investigator 1 Janssen Research & Development, LLC $5,012.00 09/18/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956829
Principal investigator 1 ModernaTX, Inc. $2,341.50 09/18/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130777
Principal investigator 1 ModernaTX, Inc. $399.12 09/16/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A PHASE 3, RANDOMIZED, OBSERVER-BLINDED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MRNA-1403, A MULTIVALENT CANDIDATE VACCINE TO PREVENT NOROVIRUS ACUTE GASTROENTERITIS IN ADULTS 18 YEARS OF AGE No dispute reported 06/30/2026 1147130953
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/12/2024 Non-covered Recipient Entity
JBR CLINICAL RESEARCH
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1147192184
Principal investigator 1 ModernaTX, Inc. $2,607.12 09/06/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147130963
Principal investigator 1 Janssen Research & Development, LLC $6,750.00 09/04/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956977
Principal investigator 1 ModernaTX, Inc. $2,500.00 09/04/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147130773
Principal investigator 1 ModernaTX, Inc. $2,000.00 09/04/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147130775
Principal investigator 1 ModernaTX, Inc. $285,480.42 09/02/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147130955
Principal investigator 1 ModernaTX, Inc. $2,070.00 08/28/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130769
Principal investigator 1 Bavarian Nordic A/S $600.00 08/23/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 1119663242
Principal investigator 1 ModernaTX, Inc. $598.68 08/20/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age No dispute reported 06/30/2026 1147130937
Principal investigator 1 Alnylam Pharmaceuticals Inc. $234.60 08/19/2024 Non-covered Recipient Entity
Suncoast Research Associates LLC
A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) No dispute reported 06/30/2026 1121160382
Principal investigator 1 Janssen Research & Development, LLC $1,728.00 08/19/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078957067
Principal investigator 1 ModernaTX, Inc. $23,415.03 08/16/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130765
Principal investigator 1 ModernaTX, Inc. $414.00 08/16/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130767
Principal investigator 1 ModernaTX, Inc. $3,450.07 08/12/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1147130941
Principal investigator 1 ModernaTX, Inc. $43,746.00 08/08/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1147130939
Principal investigator 1 ModernaTX, Inc. $45,117.05 08/07/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147130763
Principal investigator 1 ModernaTX, Inc. $49,289.88 08/01/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147130943
Principal investigator 1 Janssen Research & Development, LLC $1,956.00 07/26/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956773
Principal investigator 1 Novavax Inc $750.00 07/25/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375659
Principal investigator 1 Bavarian Nordic A/S $1,000.00 07/24/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 1119663236
Principal investigator 1 Bavarian Nordic A/S $700.00 07/24/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 1119663238
Principal investigator 1 Bavarian Nordic A/S $1,200.00 07/24/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 1119663240
Principal investigator 1 ModernaTX, Inc. $3,122.00 07/24/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130761
Principal investigator 1 ModernaTX, Inc. $10,000.00 07/15/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147130841
Principal investigator 1 ModernaTX, Inc. $25,756.53 07/03/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130759
Principal investigator 1 ModernaTX, Inc. $7,352.64 06/27/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147130919
Principal investigator 1 ModernaTX, Inc. $24,610.84 06/27/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147130929
Principal investigator 1 Bavarian Nordic A/S $3,562.41 06/26/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 1119663216
Principal investigator 1 Janssen Research & Development, LLC $978.00 06/25/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078957595
Principal investigator 1 SANOFI PASTEUR INC. $1,932.00 06/21/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699168
Principal investigator 1 SANOFI PASTEUR INC. $2,363.94 06/21/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699180
Principal investigator 1 Novavax Inc $10,434.08 06/20/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123376239
Principal investigator 1 SANOFI PASTEUR INC. $519,639.28 06/20/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699166
Principal investigator 1 SANOFI PASTEUR INC. $228,131.49 06/20/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699174
Principal investigator 1 ModernaTX, Inc. $105,504.00 06/19/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147130917
Principal investigator 1 SANOFI PASTEUR INC. $20,977.35 06/19/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699164
Principal investigator 1 ModernaTX, Inc. $23,805.80 06/17/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147130925
Principal investigator 1 Janssen Research & Development, LLC $1,956.00 06/14/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078957011
Principal investigator 1 ModernaTX, Inc. $12,762.90 06/13/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147130915
Principal investigator 1 ModernaTX, Inc. $500.00 06/12/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147130913
Principal investigator 1 ModernaTX, Inc. $775.00 06/12/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147130921
Principal investigator 1 SANOFI PASTEUR INC. $1,242.00 06/10/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699176
Principal investigator 1 SANOFI PASTEUR INC. $694.14 06/10/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699178
Principal investigator 1 ModernaTX, Inc. $1,250.00 06/05/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147130911
Principal investigator 1 SANOFI PASTEUR INC. $175.00 06/04/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699170
Principal investigator 1 SANOFI PASTEUR INC. $1,150.00 06/04/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699172
Principal investigator 1 SANOFI PASTEUR INC. $1,250.00 06/04/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699182
Principal investigator 1 ModernaTX, Inc. $15,700.00 06/03/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147130909
Principal investigator 1 ModernaTX, Inc. $100.50 05/31/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147130893
Principal investigator 1 Bavarian Nordic A/S $16,138.44 05/29/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 1119663214
Principal investigator 1 ModernaTX, Inc. $19,441.00 05/29/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147130897
Principal investigator 1 SANOFI PASTEUR INC. $146,410.77 05/28/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699152
Principal investigator 1 ModernaTX, Inc. $4,870.00 05/27/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147130899
Principal investigator 1 ModernaTX, Inc. $57,794.36 05/24/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147130749
Principal investigator 1 Janssen Research & Development, LLC $4,372.00 05/22/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078957665
Principal investigator 1 ModernaTX, Inc. $7,295.66 05/22/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130751
Principal investigator 1 ModernaTX, Inc. $3,222.75 05/22/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130753
Principal investigator 1 ModernaTX, Inc. $441.60 05/22/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130755
Principal investigator 1 ModernaTX, Inc. $500.00 05/14/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147130905
Principal investigator 1 SANOFI PASTEUR INC. $3,959.22 05/13/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699156
Principal investigator 1 SANOFI PASTEUR INC. $2,500.00 05/13/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699188
Principal investigator 1 SANOFI PASTEUR INC. $20,000.00 05/13/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699192
Principal investigator 1 SANOFI PASTEUR INC. $273.24 05/08/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699186
Principal investigator 1 SANOFI PASTEUR INC. $593.40 05/08/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699190
Principal investigator 1 SANOFI PASTEUR INC. $750.00 05/06/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699138
Principal investigator 1 SANOFI PASTEUR INC. $100.00 05/06/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699148
Principal investigator 1 ModernaTX, Inc. $20,085.26 05/03/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147130895
Principal investigator 1 SANOFI PASTEUR INC. $393,144.99 05/03/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699184
Principal investigator 1 Novavax Inc $5,174.40 05/02/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374611
Principal investigator 1 SANOFI PASTEUR INC. $750.00 04/29/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128699120
Principal investigator 1 SANOFI PASTEUR INC. $4,450.00 04/29/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128699126
Principal investigator 1 SANOFI PASTEUR INC. $1,563.00 04/29/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128699128
Principal investigator 1 SANOFI PASTEUR INC. $500.00 04/29/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128699130
Principal investigator 1 SANOFI PASTEUR INC. $900.00 04/29/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128699132
Principal investigator 1 SANOFI PASTEUR INC. $2,000.00 04/29/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128699134
Principal investigator 1 SANOFI PASTEUR INC. $5,500.00 04/29/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128699136
Principal investigator 1 SANOFI PASTEUR INC. $8,900.00 04/29/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128699142
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 04/29/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128699144
Principal investigator 1 SANOFI PASTEUR INC. $15,000.00 04/29/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128699150
Principal investigator 1 Janssen Research & Development, LLC $2,928.00 04/26/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078957171
Principal investigator 1 ModernaTX, Inc. $6,695.00 04/25/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A RANDOMIZED, OBSERVER-BLIND, ACTIVE-CONTROLLED PHASE 3 STUDY TO INVESTIGATE THE SAFETY, IMMUNOGENICITY, AND RELATIVE VACCINE EFFICACY OF MRNA-1283.222 ADMINISTERED AS A BOOSTER DOSE COMPARED WITH MRNA-1273.222 IN PARTICIPANTS AGED 12 YEARS AND OLDER FOR THE PREVENTION OF COVID-19 No dispute reported 06/30/2026 1147151469
Principal investigator 1 SANOFI PASTEUR INC. $45,073.96 04/25/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699154
Principal investigator 1 SANOFI PASTEUR INC. $1,050.00 04/25/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699158
Principal investigator 1 ModernaTX, Inc. $13,165.00 04/24/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147130735
Principal investigator 1 ModernaTX, Inc. $4,000.00 04/22/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147130889
Principal investigator 1 SANOFI PASTEUR INC. $15,555.41 04/19/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128699122
Principal investigator 1 SANOFI PASTEUR INC. $1,563.00 04/19/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128699124
Principal investigator 1 SANOFI PASTEUR INC. $3,450.00 04/19/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Parallel-group, Phase I/II, Randomized, Modified Double-blind, 3-arm, Active Comparator, Multi-center, Prevention Study to Evaluate the Immunogenicity and Safety of Two Adjuvanted Dose Levels of Panblok H7+MF59 Influenza Vaccine Compared With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older No dispute reported 06/30/2026 1128699140
Principal investigator 1 Bavarian Nordic A/S $11,973.80 04/17/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 1119663218
Principal investigator 1 ModernaTX, Inc. $1,179.00 04/17/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130739
Principal investigator 1 ModernaTX, Inc. $1,080.00 04/17/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130741
Principal investigator 1 ModernaTX, Inc. $625.00 04/17/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130743
Principal investigator 1 ModernaTX, Inc. $1,000.00 04/17/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130745
Principal investigator 1 ModernaTX, Inc. $4,880.00 04/12/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130747
Principal investigator 1 Novavax Inc $10,500.00 04/11/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123374070
Principal investigator 1 SANOFI PASTEUR INC. $1,979.61 04/11/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699160
Principal investigator 1 ModernaTX, Inc. $45,940.18 04/10/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130737
Principal investigator 1 SANOFI PASTEUR INC. $1,000.00 04/10/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699146
Principal investigator 1 SANOFI PASTEUR INC. $7,500.00 04/10/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699162
Principal investigator 1 Bavarian Nordic A/S $950.00 04/05/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 1119663220
Principal investigator 1 ModernaTX, Inc. $5,500.00 03/28/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1147130873
Principal investigator 1 ModernaTX, Inc. $47,402.05 03/28/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147130881
Principal investigator 1 Bavarian Nordic A/S $76,449.75 03/27/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119663132
Principal investigator 1 Bavarian Nordic A/S $15,442.20 03/27/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119663144
Principal investigator 1 Bavarian Nordic A/S $4,993.20 03/27/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 1119663146
Principal investigator 1 Bavarian Nordic A/S $500.00 03/27/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119663160
Principal investigator 1 Bavarian Nordic A/S $700.00 03/27/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119663162
Principal investigator 1 Bavarian Nordic A/S $2,000.00 03/27/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119663164
Principal investigator 1 Bavarian Nordic A/S $6,000.00 03/27/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119663166
Principal investigator 1 Bavarian Nordic A/S $5,257.00 03/27/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119663168
Principal investigator 1 ModernaTX, Inc. $2,070.00 03/27/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130721
Principal investigator 1 ModernaTX, Inc. $414.00 03/27/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130723
Principal investigator 1 ModernaTX, Inc. $2,000.00 03/27/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130725
Principal investigator 1 Janssen Research & Development, LLC $6,067.00 03/25/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078957591
Principal investigator 1 ModernaTX, Inc. $28,608.07 03/21/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147130871
Principal investigator 1 SANOFI PASTEUR INC. $2,400.00 03/14/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699104
Principal investigator 1 ModernaTX, Inc. $49,952.06 03/13/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130719
Principal investigator 1 ModernaTX, Inc. $31,434.40 03/13/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147130869
Principal investigator 1 SANOFI PASTEUR INC. $1,500.00 03/11/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699102
Principal investigator 1 SANOFI PASTEUR INC. $9,450.00 03/11/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699106
Principal investigator 1 SANOFI PASTEUR INC. $15,000.00 03/11/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699108
Principal investigator 1 SANOFI PASTEUR INC. $10,260.00 03/05/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699096
Principal investigator 1 SANOFI PASTEUR INC. $15,000.00 03/05/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699098
Principal investigator 1 Janssen Research & Development, LLC $14,411.00 03/04/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078957515
Principal investigator 1 ModernaTX, Inc. $900.00 03/01/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147130875
Principal investigator 1 ModernaTX, Inc. $1,769.85 02/28/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147130851
Principal investigator 1 ModernaTX, Inc. $25,788.59 02/26/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147130861
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $16,782.50 02/24/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Evaluation of Efficacy and Safety of VX-548 for Painful Diabetic Peripheral Neuropathy (DPN) No dispute reported 06/30/2026 1095480842
Principal investigator 1 ModernaTX, Inc. $500.00 02/22/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 1/2, Randomized, Open-Label Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1011.1, mRNA-1011.2, and mRNA-1012.1 Candidate Seasonal Influenza Vaccines in Healthy Adults 50 to 75 Years of Age No dispute reported 06/30/2026 1147130853
Principal investigator 1 GlaxoSmithKline, LLC. $522.48 02/21/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A PHASE 1, SINGLE-BLIND, SAFETY, REACTOGENICITY, AND IMMUNOGENICITY TR No dispute reported 06/30/2026 1127543825
Principal investigator 1 Janssen Research & Development, LLC $10,500.00 02/21/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078957317
Principal investigator 1 ModernaTX, Inc. $8,585.51 02/21/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130709
Principal investigator 1 Novavax Inc $5,000.00 02/15/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123377903
Principal investigator 1 ModernaTX, Inc. $7,250.00 02/14/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130707
Principal investigator 1 ModernaTX, Inc. $3,100.00 02/12/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147130855
Principal investigator 1 Novavax Inc $15,320.48 02/08/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES LLC
A Phase 2/3, Randomized, Double-Blind Study to Evaluate the Safety and Immunogenicity of Different Booster Dose Levels of Monovalent SARS-CoV-2 rS Vaccines in Adults older than or equal to 50 Years Previously Vaccinated With COVID-19 mRNA Vaccines No dispute reported 06/30/2026 1123375139
Principal investigator 1 SANOFI PASTEUR INC. $1,350.00 02/08/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/II, Randomized, Placebo-controlled Multi-arm Dose-finding Study to Evaluate the Safety and Immunogenicity of a RSV mRNA Vaccine Candidate With Either LNP CL-0059 or LNP CL-0137 in Adult Participants 18 to 50 Years of Age in a Sentinel Cohort and 60 Years and Older in Main and Booster Cohorts No dispute reported 06/30/2026 1128699110
Principal investigator 1 ModernaTX, Inc. $29,308.79 02/02/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147130715
Principal investigator 1 ModernaTX, Inc. $176,321.43 02/02/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, randomized, stratified, observer-blind, active-controlled study to evaluate the immunogenicity, reactogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults 18 years and older No dispute reported 06/30/2026 1147130717
Principal investigator 1 SANOFI PASTEUR INC. $8,650.00 02/02/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128699114
Principal investigator 1 Bavarian Nordic A/S $32,113.80 02/01/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 1119663136
Principal investigator 1 Bavarian Nordic A/S $892.05 02/01/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
Long-term Follow-up Study to Evaluate Safety and Immunogenicity of PXVX0317 Single or Booster Vaccination No dispute reported 06/30/2026 1119663138
Principal investigator 1 SANOFI PASTEUR INC. $6,257.62 01/31/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128699112
Principal investigator 1 SANOFI PASTEUR INC. $300.00 01/31/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adults Aged 18 Years and Older No dispute reported 06/30/2026 1128699116
Principal investigator 1 SANOFI PASTEUR INC. $1,420.00 01/29/2024 Non-covered Recipient Entity
Suncoast Research Associates Llc
A Phase I/IIa, Randomized, Observer-blind Placebo-controlled Multi-arm Study to Evaluate the Safety and Immunogenicity of an RSV/hMPV Vaccine, in Adult Participants Aged 60 Years and Older No dispute reported 06/30/2026 1128699100
Principal investigator 1 Janssen Research & Development, LLC $5,446.00 01/26/2024 Non-covered Recipient Entity
Suncoast Rsrch Associates Llc
70033093AFL3002 No dispute reported 06/30/2026 1078956929
Principal investigator 1 ModernaTX, Inc. $55,669.51 01/17/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130699
Principal investigator 1 ModernaTX, Inc. $1,340.00 01/17/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3 Randomized, Observer-Blind, Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus (RSV), When Given Alone or Coadministered with a Seasonal Influenza Vaccine or SARS-CoV-2 Vaccine and When Given as an Open-label Boost at 1 Year Following a Primary Dose in Adults 50 Years of Age No dispute reported 06/30/2026 1147130701
Principal investigator 1 ModernaTX, Inc. $439,421.95 01/17/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-Blind Study to Evaluate Safety, Tolerability, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, When Coadministered With a High-Dose, Quadrivalent Seasonal Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1147130839
Principal investigator 1 ModernaTX, Inc. $80,429.28 01/16/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 No dispute reported 06/30/2026 1147130835
Principal investigator 1 Bavarian Nordic A/S $2,000.00 01/12/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119663154
Principal investigator 1 Bavarian Nordic A/S $1,500.00 01/12/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119663156
Principal investigator 1 Bavarian Nordic A/S $1,000.00 01/12/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH ASSOCIATES
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2 No dispute reported 06/30/2026 1119663158
Principal investigator 1 ModernaTX, Inc. $1,400.00 01/12/2024 Non-covered Recipient Entity
SUNCOAST RESEARCH GROUP LLC
A Phase 3, Randomized, Observer-blind, Active-controlled Study to Evaluate the Safety and Efficacy of mRNA-1010 Candidate Seasonal Influenza Vaccine in Adults 50 Years and Older No dispute reported 06/30/2026 1147130833